Bodisen Biotech Reports Record Second Quarter Financial Results
16 August 2006
(1,093,797) --
------------- ------------- ------------- ------------- Comprehensive Income $ 2,653,701 $ 2,692,014 $ 7,586,627 $ 3,488,746 ============= ============= ============= =============
Weighted average shares outstanding: Basic 18,176,917 15,272,926 17,698,731 15,270,759 ============= ============= ============= ============= Diluted 18,310,931 15,692,205 17,848,452 15,562,010 ============= ============= ============= =============
Earnings per share: Basic $ 0.32 $ 0.18 $ 0.48 $ 0.23 ============= ============= ============= ============= Diluted $ 0.32 $ 0.17 $ 0.48 $ 0.22 ============= ============= ============= =============
BODISEN BIOTECH, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2006 (UNAUDITED)
ASSETS ------ CURRENT ASSETS: Cash & cash equivalents $17,447,381 Accounts receivable, net of allowance for doubtful accounts of $697,209 17,613,943 Other receivable 1,526,114 Inventory 1,145,025 Advances to suppliers 8,934,286 Prepaid expense 47,714 Other current assets 2,083
---------- Total current assets 46,716,546
PROPERTY AND EQUIPMENT, net 5,160,897
CONSTRUCTION IN PROGRESS 2,618,316
MARKETABLE SECURITY 5,716,637
INTANGIBLE ASSETS 2,072,233
---------- TOTAL ASSETS $62,284,629 ==========
LIABILITIES AND STOCKHOLDERS' EQUITY ------------------------------------
CURRENT LIABILITIES: Accounts payable $ 1,852,149 Other payables 154,246 Accrued expenses 497,017
---------- Total current liabilities 2,503,412
STOCKHOLDERS' EQUITY: Preferred stock, $0.0001 per share; authorized 5,000,000 shares; none issued Common stock, $0.0001 per share; authorized 30,000,000 shares; issued and outstanding 18,176,917 1,818 Additional paid-in capital 32,860,075 Other comprehensive income 3,555,315 Statutory reserve 3,742,991 Retained earnings 19,621,018 ---------- Total stockholders' equity 59,781,217
---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $62,284,629 ==========
Investor Relations: Debra Chen The Piacente Group, Inc. 212-481-1907
SOURCE: Bodisen Biotech
Source: marketwire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
